Pitolisant Hydrochloride Drug Due Diligence Report 2026

This Pitolisant Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Pitolisant Hydrochloride can convert its Small molecule drug profile and H3 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pitolisant Hydrochloride (query alias: pitolisant)
Modality / target	Small molecule drug; H3 receptor; H3 receptor antagonists
Highest global status	Approved
Originator	Bioprojet Pharma SARL
Active developers	Bioprojet Pharma SARL, Harmony Biosciences Holdings, Inc., Harmony Biosciences Management, Inc.

The MCP disease footprint includes Excessive Daytime Sleepiness, Sleep Apnea, Obstructive, Cataplexy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07675135	Phase 3	Recruiting	258	Change in severity of EDS as measured by the Epworth Sleepiness Scale (ESS)
NCT07500090	Phase 3	Recruiting	248	Change in severity of EDS as measured by the Epworth Sleepiness Scale (ESS)
NCT07219485	Phase 3	Enrolling by invitation	150	Percentage of participants reporting Treatment-Emergent Adverse Events (TEAEs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome

Phase 2; n=65; evaluation: Positive. Reported fields: ESS-CHAD = -5.0 score ; ESS-CHAD = -3.5 score ; ESS-CHAD = -3.9 score

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Phase 2; n=65; evaluation: not stated. Reported fields: Excessive Daytime Sleepiness(Least Squares Mean) = -5.0 score on a scale (Standard Error, 1.07); Excessive Daytime Sleepiness(Least Squares Mean) = -3.9 score on a scale (Standard Error, 1.08); -

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1, Followed by an Open-Label Extension

Phase 2; n=30; evaluation: not stated. Reported fields: Change in Excessive Daytime Sleepiness (EDS) Based on Change in Daytime Sleepiness Scale (DSS) Score(Mean) = 0.0 score on a scale (Standard Deviation, 2.29); Change in Excessive Daytime Sleepiness (EDS) Based on Change in Daytime Sleepiness Scale (DSS) Score(Mean) = -1.8 score on a scale (Standard Deviation, 1.91); -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pitolisant Hydrochloride addresses Excessive Daytime Sleepiness, Sleep Apnea, Obstructive, Cataplexy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-11-10	华润三九宣布获得一款创新药中国大陆独占权利	Approved	Financial terms not disclosed
2022-06-14	Acino partners with Bioprojet to market, distribute, and commercialize pitolisant for narcolepsy and OSA in Saudi Arabia and the Middle East.	Approved	Financial terms not disclosed
2021-10-28	Aculys Pharma partners with Bioprojet to develop and commercialize pitolisant for sleep disorders in Japan.	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Stable pitolisant liquid formulations and method of its use”. The milestone feed surfaced a patent-application signal described as “Co-crystals of pitolisant hydrochloride”. The milestone feed surfaced a patent-application signal described as “Enteric coated pitolisant formulations and methods of use”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO